PolyPid (PYPD) Projected to Post Quarterly Earnings on Wednesday

PolyPid (NASDAQ:PYPD) is expected to announce its Q4 2025 results before the market opens on Wednesday, February 11th. Analysts expect PolyPid to post earnings of ($0.34) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 8:30 AM ET.

PolyPid (NASDAQ:PYPD) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.17.

PolyPid Stock Down 2.7%

PYPD stock opened at $4.74 on Wednesday. The business has a 50 day moving average price of $4.27 and a two-hundred day moving average price of $3.77. PolyPid has a twelve month low of $2.30 and a twelve month high of $5.12. The company has a market cap of $75.37 million, a price-to-earnings ratio of -1.59 and a beta of 1.52.

Institutional Trading of PolyPid

An institutional investor recently raised its position in PolyPid stock. BNP Paribas Financial Markets boosted its stake in PolyPid Ltd. (NASDAQ:PYPD) by 56.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 9,734 shares of the company’s stock after buying an additional 3,500 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.06% of PolyPid worth $32,000 as of its most recent SEC filing. Institutional investors own 26.47% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on PYPD. Roth Mkm lowered their price target on PolyPid from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Thursday, November 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of PolyPid in a research note on Monday, December 29th. Citigroup reiterated a “market outperform” rating on shares of PolyPid in a research report on Monday, December 1st. Finally, Wall Street Zen upgraded shares of PolyPid from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.25.

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.